You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
國藥中國生物預期今年新冠疫苗產能可達10億劑以上
阿思達克 02-08 12:31
國藥集團中國生物技術董事長楊曉明表示,預計今年公司新冠疫苗的產能可達10億劑以上,助力全球疫苗公平分配,從企業的角度講,就是在安全規範的前提下更多、更快生產出高質量的疫苗。

他指,目前國藥集團中國生物新冠滅活疫苗已在匈牙利、塞舌爾、巴基斯坦、摩洛哥等十多個國家和地區獲批緊急使用,在阿拉伯聯合酋長國、巴林註冊上市,在中國獲批附條件上市。

他表示,現在研發生產工藝與幾十年前的滅活疫苗工藝已經完全不一樣了,可以說是脫胎換骨的變化——工藝上有提升、技術上有突破,採用了先進的細胞培養技術、純化工藝技術等,生產效率高,質量控制指標已達到國際先進水平。

他又指,目前國藥集團中國生物等生產的國產疫苗出口供應的國家多為發展中國家,這些國家基本沒有能力研發或生產新冠疫苗,相比其他國家更需要疫苗,中國企業正為促進疫苗公平分配盡應盡的義務。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account